Anzeige
Mehr »
Login
Dienstag, 04.03.2025 Börsentäglich über 12.000 News von 689 internationalen Medien
Mit Vollgas Richtung Expansion - Gelingt nun der Durchbruch?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XAEB | ISIN: FR0011648971 | Ticker-Symbol: 2QG
Lang & Schwarz
04.03.25
09:41 Uhr
0,073 Euro
-0,073
-100,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
QUANTUM GENOMICS SAS Chart 1 Jahr
5-Tage-Chart
QUANTUM GENOMICS SAS 5-Tage-Chart
RealtimeGeldBriefZeit
0,0720,07509:42
Actusnews Wire
762 Leser
Artikel bewerten:
(2)

QUANTUM GENOMICS: Quantum Genomics reviewed its financial situation and announced that it has filed a declaration of cessation of payment today

Finanznachrichten News

Press Realse

Paris, 09 :04/2024, 18h 00

Quantum Genomics reviewed its financial situation and announced that it has filed a declaration of cessation of payment today

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC) provides an update on its financial situation and announces that it has today filed a declaration of cessation of payments with the Paris Commercial Court.

As a reminder, following the failure of the REFRESH Phase III trial on firibastat in October 2022, Quantum Genomics restructured its workforce and supplier debt during 2023, in order to reposition its business.

On April 24, 2024, the Company benefited from a contribution of Exactcure shares, giving it 100% ownership of Exactcure, which is developing an innovative software solution to improve the way drugs are taken. Since its merger with Exactcure, Quantum Genomics has been financing the activities of its subsidiary until it achieves more significant sales.

Against this background, the Company entered several negotiations with investors to raise funds to cover its cash requirements and those of its subsidiary Exactcure. These negotiations have not been successful.

The Company therefore acknowledges that it no longer has sufficient funds available to meet its current liabilities.

As a result, it has today filed a declaration of cessation of payments with the Commercial Court and requested the commencement of judicial winding-up proceedings.

At the same time, Exactcure has also filed a declaration of cessation of payments and is seeking the commencement of judicial winding-up proceedings.

It's crucial to bring to investors' attention that, considering the Company's liabilities and the estimated value

of the assets, any proceeds from the sale of assets should not be distributed to Quantum Genomics' s

shareholders

Regular press releases will be issued as the process continues.

Contacts

Quantum Genomics

contact@quantum-genomics.com

Valfa Communication (EUROPE)

Communication financière et médias

irquantumgenomics@gmail.com

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: yG5rkpyYaZecmZtxl8ZtmmVqZpxox2acbWOelpOeY53GmGlkyWqVl5XLZnFomW5u
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-87498-cp-cessation-ang.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2024 Actusnews Wire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.